Protagonist Therapeutics Inc

NASDAQ:PTGX  
31.03
-0.16 (-0.51%)
Products, Regulatory

Protagonist Announces Plans To Initiate A Global Phase 3 Study For Rusfertide In Polycythemia Vera

Published: 03/22/2021 21:25 GMT
Protagonist Therapeutics Inc (PTGX) - Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions With the U.S. Food & Drug Administration and the European Medicines Agency.
Protagonist - End-of-phase-2 Meeting With FDA, & Written Comments From Ema, Support Advancement of Clinical Development Plan for Rusfertide in Pv.